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Abstract
Background: Aiming at rapid decrease of disease activity, there has been a trend to start with higher doses of
methotrexate (MTX) in patients newly diagnosed with rheumatoid arthritis (RA), both as monotherapy and in
combination with other antirheumatic drugs. We aimed to study the relationship between clinical response and
MTX dose as monotherapy or combination therapy in patients with early RA.
Methods: Disease-modifying anti-rheumatic drug (DMARD)-naive patients with early RA, from a large international
observational database, the METEOR database, were selected if MTX was part of their initial treatment. Patients were
divided into four groups: MTX monotherapy, MTX + convention synthetic (cs)DMARDs, MTX + glucocorticoids or
MTX + biologic (b)DMARDs. MTX dose was dichotomized: low dose ≤10 mg/week; high dose ≥15 mg/week. Linear
mixed model analyses for the Disease Activity Score (DAS), DAS in 28 joints (DAS28) and Health Assessment
Questionnaire (HAQ) were performed in each medication group, with MTX dose and time as covariates. Outcomes
were assessed from baseline until 3–6 months follow up. Associations were adjusted for potential confounding by
indication using propensity score (PS) modelling.
Results: For patients starting MTX monotherapy (n = 523), MTX + csDMARDs (n = 266) or MTX + glucocorticoids
(n = 615), the PS-adjusted effects of MTX dose (high versus low) on the DAS, DAS28 and HAQ were small and
not clinically meaningful. Patients starting MTX + bDMARDs were disregarded due to low numbers (n =11).
Conclusions: In patients newly diagnosed with RA, no clinical benefit of high compared to low initial MTX
doses was found for MTX monotherapy or for MTX combination therapy with csDMARDs or glucocorticoids.
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Background
Methotrexate (MTX) is the anchor drug in the treatment
of rheumatoid arthritis (RA). Current recommendations
for MTX monotherapy suggest initiation of 15 mg/week
orally, and escalation with 5 mg/month to 25–30 mg/week
or the highest tolerable dose [1, 2]. There are no specific
recommendations for use of MTX in combination with
other antirheumatic drugs (glucocorticoids, conventional
synthetic disease-modifying antirheumatic drugs
(csDMARDs) and/or biologic DMARDs (bDMARDs)).
Many studies have shown faster reduction of disease activ-
ity, quicker improvement in physical functioning and less
radiographic evidence of damage progression on MTX
combination therapy than on MTX monotherapy [3–6]. It
is questionable whether a higher initial MTX dose in com-
bination with other effective medication is more effective
in the short term than a lower initial MTX dose. The
CONCERTO study compared four treatment arms with
different MTX doses (2.5, 5, 10 or 20 mg/week) in combin-
ation with adalimumab 40 mg/2 weeks in patients with
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early RA [7]. More patients achieved the Disease Activity
Score in 28 joints (DAS28) low disease activity or remis-
sion status with increasing MTX doses over 26 weeks.
However, radiographic progression and the Health Assess-
ment Questionnaire (HAQ) scores were similar in the vari-
ous arms. The proportions of patients achieving low
disease activity or remission were similar in the MTX
10 mg/week and MTX 20 mg/week arms.
Recently, a meta-regression analysis of trials in patients
with recent onset RA showed that higher initial MTX doses
were not associated with better short-term clinical out-
comes, neither with MTX monotherapy, nor with MTX in
combination with bDMARDs or glucocorticoids [8].
In the current study we aimed to assess the influence
of MTX dose on disease outcomes and physical func-
tioning in an international cohort with real-life data. We
hypothesized that in patients newly diagnosed with RA
the initial MTX dose as monotherapy or in combination
with other csDMARDs, bDMARDs or glucocorticoids
will not determine short-term outcomes.
Methods
Data selection
Data from the international, observational, Measurement
of Efficacy of Treatment in the Era of Outcome in
Rheumatology (METEOR) database were used, which has
been described previously [9]. For the current study, we
selected all DMARD-naive patients with early RA and
symptom duration <5 years, with ≥ 1 follow-up visits after
3–6 months. At both baseline and follow-up visits, pa-
tients had to have at least one of the following outcome
measures: DAS, DAS28, erythrocyte sedimentation rate
(ESR), C-reactive protein (CRP) or HAQ. MTX had to be
part of the initial treatment as monotherapy or in combin-
ation with other csDMARDs/bDMARDs/glucocorticoids.
Variation in dose was allowed (e.g. step-up MTX dose or
step-down prednisone dose) but no change in medication
type was allowed between initial treatment and the follow-
up visit after 3–6 months. Since the METEOR database
consists of observational data gathered in clinical practice,
there are irregular time intervals between follow-up visits
and the number of follow-up visits differs per patient.
Therefore, the last visit within 3–6 months after treatment
initiation, meeting all inclusion and exclusion criteria was
defined for each patient, and all follow-up visits between
baseline and this last follow-up visit were selected. In
order to take into account step-up dosing schedules, the
MTX dose prescribed at the final visit before 3 months
follow up was used.
Statistical analysis
Patients were analysed in four groups, based on initial
MTX strategy: (1) MTX monotherapy, (2) MTX + other
csDMARDs, (3) MTX + glucocorticoid (+/− additional
csDMARDs) or (4) MTX + bDMARD (+/− additional
csDMARDs). Missing data were imputed using multi-
variate normal multiple imputation (30 cycles). Linear
mixed model (LMM) analyses were performed to assess
the effectiveness of MTX dose on the outcome measures
DAS, DAS28 and HAQ, within the four groups. To ac-
count for irregular time intervals, random intercept and
slope were added to each model, with “independence”
covariance matrix. MTX dose was dichotomized (low
dose ≤10 mg/week; high dose ≥15 mg/week). Time in
days between baseline and each follow-up visit was
added as continuous variable.
Differences in environmental and patient character-
istics may affect the initial MTX dose, and therefore
may have caused confounding by indication. To ad-
just for potential confounding, the propensity score
(PS) was calculated in the imputed dataset, using
multiple probit regression analysis based on observed
baseline patient and environmental characteristics
[10]. Several PS models were tested and compared for
the best data fit in all 30 imputations. Representing
the probability of receiving an intervention given the
observed baseline variables, the PS was then added as
covariate adjustment to the LMM analyses. Details on
the PS are given in Additional file 1. All LMM ana-
lyses were performed with and without PS, to see
whether confounding by indication was present. All
analyses were performed using STATA SE 14 (Stata-
Corp LP).
Results
From the METEOR database, 1438 patients (3193 visits)
were selected: 523 patients (1120 visits) started MTX
monotherapy, 266 patients (581 visits) started MTX +
csDMARDs, 615 patients (1416 visits) started MTX +
glucocorticoids and 11 patients (26 visits) started MTX
+ bDMARDs (Fig. 1). Detailed information on concomi-
tant treatment is presented in Additional file 2. Patients
originated from 20 different countries, with 94% of data
originating from India, South-Africa, Portugal, the
Netherlands, the USA, Ireland and Mexico. Too few pa-
tients started MTX + bDMARDs to perform meaningful
analyses. In addition, 23 patients (50 visits) who started
MTX 12.5 mg/week (the intermediate dose) were disre-
garded. Baseline characteristics of the other patients are
shown in Table 1. There was a trend over time to start
higher MTX doses (Additional file 3).
Because physicians were free to choose their own
disease activity measure, the DAS and DAS28 based
on ESR were missing in 40% and 35% of all visits, re-
spectively. However, an official disease activity meas-
ure was only unavailable in 4% of all visits and a
disease activity measure component was only unavail-
able in 0.3% of all visits.
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In Table 2, the PS-adjusted and unadjusted coefficients
for the association between initial MTX dose and out-
comes within 3–6 months follow-up are presented,
stratified by treatment group. For patients starting MTX
monotherapy, MTX + csDMARDs or MTX + glucocorti-
coids, the PS-adjusted effects of MTX dose (high vs low)
on DAS, DAS28 and HAQ were small and not clinically
meaningful. For example, in the MTX monotherapy
group, β (95% CI) for the outcome DAS was 0.070
(−0.15; 0.29), indicating an increase in DAS of 0.070 for
a high versus a low MTX dose.
The unadjusted main associations between MTX dose
and outcomes were often in an opposite direction and/
or much larger than the PS-adjusted associations, sug-
gesting that confounding by indication indeed plays a
role and that it has been (at least partly) corrected for by
adjusting for the PS. Two sensitivity analyses were per-
formed: one excluding the country, which added most
patients to the analyses (India) and one excluding all pa-
tients with a symptom duration >2 years; both resulted
in similar outcomes (data not shown).
Discussion
In this study based on daily practice treatment decisions
in patients newly diagnosed with RA, we did not identify
clinical benefit of high compared to low MTX starting
doses in monotherapy or in combination with csDMARDs
or glucocorticoids: high initial MTX doses did not result
in greater improvement in the DAS, DAS28 or HAQ
compared to low initial MTX doses. Co-medication with
csDMARDs or glucocorticoids did not influence this ef-
fect. In an earlier meta-regression analysis we showed that
also in clinical trials there was no early clinical benefit of a
high compared to a low MTX starting dose [8].
We observed a trend over time in daily practice to start
higher MTX doses. In particular patients receiving co-
medication with glucocorticoids as initial treatment were
prescribed higher MTX doses, possibly as the rheumatolo-
gist estimated their RA to be more severe. Although we
used PS to adjust for baseline differences that may have
influenced the treatment decisions of the rheumatologist
as well as the outcomes, intangible or unmeasured base-
line differences may still affect the results.
We assessed response to treatment within 3–6 months,
since current recommendations advise a treat-to-target
strategy in which medication is intensified or changed as
soon as possible if treatment is not effective. The more
rapid onset of action of glucocorticoids as co-treatment
may mask any effect of the initial dose of slow-acting
MTX [3, 11]. As demonstrated in clinical trials, this ap-
pears also to be true for initial treatment with bDMARDs
and MTX, but as this is a rare initial treatment in daily
practice, we were unable to investigate this further. How-
ever, also with MTX monotherapy a higher dose was not
more effective than a low dose. The most likely explan-
ation is in the pharmacokinetics of MTX, where stable
availability of active MTX polyglutamates seems inde-
pendent of the weekly MTX dose [12].
This study has potential limitations. The effect of
MTX dose was assessed within three subgroups de-
pending on the use and type of co-medication, but
within each group, variations in type, number and dose
of additional drugs in individual patients could
Fig. 1 Flow chart of the patient selection
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influence efficacy. However, previous clinical trials have
shown comparable disease outcomes of various com-
bination therapies and dosing schedules for many drugs
are fixed [13, 14]. We dichotomized MTX dosage, and
defined MTX >15 mg/week as high dose, which is used
in current recommendations, but is still an arbitrary
cutoff. The results might have been slightly different
with other cutoffs. In addition, MTX was mostly ad-
ministered orally, and uptake can vary between individ-
uals. We have no further data on the number and
timing of patients who might have switched to subcuta-
neous treatment. The results might have been different
with subcutaneous administration of MTX. Moreover,
although we are unaware of any evidence that the re-
sponse to methotrexate could differ between the coun-
tries included in the analysis, we took into account the
potential influence of country on our outcomes and ad-
justed for potential country differences by adding coun-
try to the propensity score.
Since real-world data were used, no formal procedures
were taken to control the quality of clinical assessments,
which may have led to more noise compared to clinical
trial data. However, our data are in line with previous
findings [8].
Table 1 Baseline characteristics per treatment group, non-imputed data
MTX monotherapy (n = 523) MTX + csDMARDs (n = 266) MTX + glucocorticoids (n = 615)
Number Number Number
Age at first visit (years) 522 47.9 (13.1) 264 44.6 (10.9) 479 48.3 (14.8)
Gender (% female) 520 78 266 83 609 81
Body mass index 281 26.6 (6.7) 184 27.6 (6.3) 272 27.2 (6.0)
Symptom duration at diagnosis median (IQR) 451 365 (169–731) 266 730 (365–1095) 482 458 (181–1095)
Rheumatoid factor (% positive) 511 77 263 84 585 81
ACPA (% positive) 300 72 98 85 342 76
Erosions present (% positive) 305 40 62 55 293 52
ESR 462 56.5 (33.0) 241 69.3 (31.7) 543 59.5 (35.5)
CRP 415 33.1 (33.9) 219 40.3 (35.5) 515 37.7 (37.1)
HAQ 439 1.0 (0.6) 249 1.1 (0.6) 506 1.3 (0.7)
DAS 314 3.7 (1.2) 189 4.0 (0.96) 347 3.9 (1.2)
DAS 28 340 5.7 (1.5) 192 6.2 (1.2) 415 6.0 (1.5)
MTX dose (% high dose) 523 28 266 14 615 46
Follow-up duration (days) 523 134 (28) 266 135 (28) 615 139 (31)
Data per number of patients are means (SD), unless indicated otherwise. MTX methotrexate, csDMARDs conventional synthetic disease-modifying antirheumatic
drugs, IQR inter quartile range, ACPA anti-citrullinated protein antibodies, ESR erythrocyte sedimentation rate, CRP C-reactive protein, HAQ Health Assessment
Questionnaire, DAS Disease Activity Score
Table 2 Unadjusted and propensity score-adjusted results of the linear mixed model analyses to investigate the effectiveness








Methotrexate monotherapy (number of patients = 522, number of visits = 1090)
MTX dose group PS-adjusted 0.070 (−0.15; 0.29) 0.12 (−0.19; 0.43) 0.060 (−0.09; 0.21
MTX dose group unadjusted −0.63 (−0.79; −0.47) −0.90 (−0.13; −0.67) 0.16 (0.055; 0.26)
Methotrexate + csDMARDs (number of patients = 262, number of visits = 567)
MTX dose group PS-adjusted 0.051 (−0.23; 0.33) 0.024 (−0.37; 0.42) −0.0058 (−0.20; 0.19)
MTX dose group unadjusted −0.18 (−0.44; 0.072) −0.28 (−0.63; 0.072) 0.092 (−0.085; 0.27)
Methotrexate + oral glucocorticoid (+/−csDMARDs) (number of patients = 615, number of visits = 1403)
MTX dose group PS-adjusted −0.047 (−0.26; 0.16) −0.16 (−0.44; 0.12) −0.028 (−0.16; 0.11)
MTX dose group unadjusted −0.42 (−0.56; 0.28) −0.74 (−0.93; −0.55) 0.13 (0.045; 0.22)
Time is modelled in days between the baseline visit and each follow-up visit. Low dose is the reference category. MTX dose group is a binary variable with low
dose ≤10 mg/week and high dose ≥15 mg/week. DAS Disease Activity Score, DAS 28 Disease Activity Score in 28 joints, HAQ Health Assessment Questionnaire, PS
propensity score, 95% CI 95% confidence interval, MTX methotrexate, csDMARDs conventional synthetic disease-modifying antirheumatic drug
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Conclusion
In conclusion, these real-world data show that in pa-
tients newly diagnosed with RA, a higher MTX dose
with or without other csDMARD or glucocorticoids
does not result in better clinical efficacy after 3–6
months compared to a low dose. This seems to contra-
dict a general trend over time to start with higher MTX
doses. Without apparent early benefit, higher initial
MTX dosages may introduce more side effects, which
may jeopardise drug retention. However, since side ef-
fects were not measured in the METEOR database, we
could not assess this. On the other hand, starting a low
MTX dose may induce delays in suppression of disease
activity and in the introduction of additional therapies,
as up to 23% of patients have been found to require
higher dosage and up to 56% have not been found to
achieve low disease activity with MTX [15]. For the mo-
ment, our results suggest that although with MTX
monotherapy there may be other considerations, rheu-
matologists should consider a low instead of a high ini-
tial MTX dose, in particular when prescribed in
combination with other csDMARDs or glucocorticoids,
and further modify treatment according to a treat-to-
target protocol.
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